Membrane Transporters in Drug Development

Advances in Pharmacology

Volumn 63, Issue , 2012, Pages 1-42

  Keogh, J P ^a  

^a Independent DMPK Consultant   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMILORIDE; CIMETIDINE; DIGOXIN; ETHIDIUM BROMIDE; FEXOFENADINE; GABAPENTIN ENACARBIL; GLYCOPROTEIN P; IVERMECTIN; MEMBRANE PROTEIN; METFORMIN; METHOTREXATE; MULTIDRUG RESISTANCE PROTEIN 4; OCTAMER TRANSCRIPTION FACTOR 4; PENICILLIN G; PRAVASTATIN; PROBENECID; ROSUVASTATIN; SALAZOSULFAPYRIDINE; TRAMADOL; XENOBIOTIC AGENT;

ARTICLE; DRUG ABSORPTION; DRUG DEVELOPMENT; DRUG DISPOSITION; DRUG ELIMINATION; DRUG HALF LIFE; GENETIC POLYMORPHISM; HUMAN; MEMBRANE PERMEABILITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SPECIES DIFFERENCE; TISSUE DISTRIBUTION;

EID: 84863767836     PISSN: 10543589     EISSN: 15578925     Source Type: Book Series    
DOI: 10.1016/B978-0-12-398339-8.00001-X     Document Type: Chapter

References (107)

1. Acharya P., O'Connor M.P., Polli J.W., Ayrton A., Ellens H., Bentz J. Kinetic identification of membrane transporters that assist P-glycoprotein-mediated transport of digoxin and loperamide through a confluent monolayer of MDCKII-hMDR1 cells. Drug Metabolism and Disposition 2008, 36(2):452-460.
2. Adkison K.K., Vaidya S.S., Lee D.Y., Koo S.H., Li L., Mehta A.A., et al. Oral sulfasalazine as a clinical BCRP probe substrate: pharmacokinetic effects of genetic variation (C421A) and pantoprazole coadministration. Journal of Pharmaceutical Sciences 2010, 99(2):1046-1062.
3. Agarwal S., Sane R., Ohlfest J., Elmquist W. The role of the breast cancer resistance protein (ABCG2) in the distribution of sorafenib to the brain. Journal of Pharmacology and Experimental Therapeutics 2011, 336(1):223-233.
4. Agnani D., Acharya P., Martinez E., Tran T.T., Abraham F., Tobin F., et al. Fitting the elementary rate constants of the P-gp transporter network in the hMDR1-MDCK confluent cell monolayer using a particle swarm algorithm. PLoS One 2011, 6(10):e25086.
5. Akamine Y., Miura M., Yasai-Furukori N., Kojima M., Uno T. Carbamazepine Differentially Affects the Pharmacokinetics of Fexofenadine Enantiomers 2011.
6. Ayrton A., Morgan P. Role of transport proteins in drug discovery and development: a pharmaceutical perspective. Xenobiotica 2008, 38(7, 8):676-708.
7. Benet L.Z., Amidon G.L., Barends D.M., Lennernas H., Polli J.E., Shah V.P., et al. The use of BDDCS in classifying the permeability of marketed drugs. Pharmaceutical Research 2008, 25(3):483-488.
8. Bhattachar S.N., Perkins E.J., Tan J.S., Burns L.J. Effect of gastric pH on the pharmacokinetics of a BCS class II compound in dogs: utilization of an artificial stomach and duodenum dissolution model and GastroPlus, simulations to predict absorption. Journal of Pharmaceutical Sciences 2011, 100(11):4756-4765.
9. Biermann J., Lang D., Gorboulev V., Koepsell H., Sindic A., Schroter R., et al. Characterization of regulatory mechanisms and states of human organic cation transporter 2. Am. J. Physiol Cell Physiol 2006, 290,(6):C1521-C1531.
10. Brown C., Sayer C., Windass A., Haslam I., De Broe M., D'Haese P., et al. Characterisation of human tubular cell monolayers as a model of proximal tubular xenobiotic handling. Toxicology and Applied Pharmacology 2008, 233(3):428-438.
11. Burnell J.M., Kirby W.M. Effectiveness of a new compound, benemid, in elevating serum penicillin concentrations. Journal of Clinical Investigation 1951, 30(7):697-700.
12. Chiba M., Ishii Y., Sugiyama Y. Prediction of hepatic clearance in human from in vitro data for successful drug development. AAPS Journal 2009, 11(2):262-276.
13. Dawson P., Hubbert M.L., Rao A. Getting the mOST from OST: Role of organic solute transporter, OSTalpha-OSTbeta, in bile acid and steroid metabolism. Biochimica et Biophysica Acta 2010, 1801(9):994-1004.
14. Dawson S., Stahl S., Paul N., Barber J., Kenna J.G. In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans. Drug Metabolism and Disposition 2012, 40(1):130-138.
15. de Klerk O.L., Willemsen A.T., Bosker F.J., Bartels A.L., Hendrikse N.H., den Boer J.A., et al. Regional increase in P-glycoprotein function in the blood-brain barrier of patients with chronic schizophrenia: a PET study with [(11)C]verapamil as a probe for P-glycoprotein function. Psychiatry Research 2010, 183(2):151-156.
16. Guideline on The Investigation of Drug Interactions 2010, European Medicines Agency, (February 21, 2012). http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/05/WC500090112.pdf.
17. Drug Development and Drug Interactions: Possible Models for Decision-Making 2012, Food and Drugs Administration, (February 21, 2012). http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093583.htm.
18. Guidance for Industry Drug Interaction Studies - Study Design, Data Analysis, and Implications for Dosing and Labeling 2006, Food and Drugs Administration, (February 20, 2012). http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072101.pdf.
19. Foti R.S., Rock D.A., Wienkers L.C., Wahlstrom J.L. Selection of alternative CYP3A4 probe substrates for clinical drug interaction studies using in vitro data and in vivo simulation. Drug Metabolism and Disposition 2010, 38(6):981-987.
20. Generaux G.T., Bonomo F.M., Johnson M., Doan K.M. Impact of SLCO1B1 (OATP1B1) and ABCG2 (BCRP) genetic polymorphisms and inhibition on LDL-C lowering and myopathy of statins. Xenobiotica 2011, 41(8):639-651.
21. Giacomini K.M., Huang S.M., Tweedie D.J., Benet L.Z., Brouwer K.L., Chu X., et al. Membrane transporters in drug development. Nature Reviews Drug Discovery 2010, 9(3):215-236.
22. Gutman A.B., Yu T.F. Renal function in gout; with a commentary on the renal regulation of urate excretion, and the role of the kidney in the pathogenesis of gout. American Journal of Medicine 1957, 23(4):600-622.
23. Gutman A.B., Yu T.F. Renal regulation of uric acid excretion in normal and gouty man; modification by uricosuric agents. Bulletin of the New York Academy of Medicine 1958, 34(5):287-296.
24. Hallifax, D., Turlizzi, E., Zanelli, U., & Houston, J.B. (2011). Clearance-dependent underprediction of in vivo intrinsic clearance from human hepatocytes: comparison with permeabilities from artificial membrane (PAMPA) assay, in silico and caco-2 assay, for 65 drugs. PM:22214813 (February 23, 2012).
25. Heddiger, M. A. (2010). SLC tables. Available from: , February 21, 2012. http://www.bioparadigms.org/.
26. Ho R.H., Tirona R.G., Leake B.F., Glaeser H., Lee W., Lemke C.J., et al. Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics. Gastroenterology 2006, 130(6):1793-1806.
27. Hobbs M., Parker C., Birch H., Kenworthy K.E. Understanding the interplay of drug transporters involved in the disposition of rosuvastatin in the isolated perfused rat liver using a physiologically-based pharmacokinetic model 2011.
28. Ieiri I., Higuchi S., Sugiyama Y. Genetic polymorphisms of uptake (OATP1B1, 1B3) and efflux (MRP2, BCRP) transporters: implications for inter-individual differences in the pharmacokinetics and pharmacodynamics of statins and other clinically relevant drugs. Expert Opinion on Drug Metabolism & Toxicology 2009, 5(7):703-729.
29. Jamei M., Marciniak S., Feng K., Barnett A., Tucker G., Rostami-Hodjegan A. The Simcyp population-based ADME simulator. Expert Opinion on Drug Metabolism & Toxicology 2009, 5(2):211-223.
30. Jeffrey S., Summerfield S. Assessment of the blood-brain barrier in CNS drug discovery. Neurobiology of Disease 2010, 37(1):33-37.
31. Jemnitz K., Veres Z., Tugyi R., Vereczkey L. Biliary efflux transporters involved in the clearance of rosuvastatin in sandwich culture of primary rat hepatocytes. Toxicology In Vitro 2010, 24(2):605-610.
32. Johnson B.M., Zhang P., Schuetz J.D., Brouwer K.L. Characterization of transport protein expression in multidrug resistance-associated protein (Mrp) 2-deficient rats. Drug Metabolism and Disposition 2006, 34(4):556-562.
33. Kajosaari L.I., Niemi M., Neuvonen M., Laitila J., Neuvonen P.J., Backman J.T. Cyclosporine markedly raises the plasma concentrations of repaglinide. Clinical Pharmacology & Therapeutics 2005, 78(4):388-399.
34. Kell D.B., Dobson P.D., Oliver S.G. Pharmaceutical drug transport: the issues and the implications that it is essentially carrier-mediated only. Drug Discovery Today 2011, 16(15, 16):704-714.
35. Kelly R., Draper D., Chen C.C., Robey R.W., Figg W.D., Piekarz R.L., et al. A pharmacodynamic study of docetaxel in combination with the P-glycoprotein antagonist tariquidar (XR9576) in patients with lung, ovarian, and cervical cancer. Clinical Cancer Research 2011, 17(3):569-580.
36. Keppler D. Cholestasis and the role of basolateral efflux pumps. Zeitschrift fur Gastroenterologie 2011, 49(12):1553-1557.
37. Kharasch E.D., Bedynek P.S., Walker A., Whittington D., Hoffer C. Mechanism of ritonavir changes in methadone pharmacokinetics and pharmacodynamics: II. Ritonavir effects on CYP3A and P-glycoprotein activities. Clinical Pharmacology & Therapeutics 2008, 84(4):506-512.
38. Kitamura S., Maeda K., Sugiyama Y. Recent progresses in the experimental methods and evaluation strategies of transporter functions for the prediction of the pharmacokinetics in humans. Naunyn-Schmiedebergs Archives of Pharmacology 2008, 377(4-6):617-628.
39. Knut and Alice Wallenberg Foundation (2011). The Human Protein Atlas. Available from: (February 20, 2012). http://www.proteinatlas.org/.
40. Kolhatkar V., Polli J.E. Reliability of inhibition models to correctly identify type of inhibition. Pharmaceutical Research 2010, 27(11):2433-2445.
41. Kotani N., Maeda K., Watanabe T., Hiramatsu M., Gong L.K., Bi Y.A., et al. Culture period-dependent changes in the uptake of transporter substrates in sandwich-cultured rat and human hepatocytes. Drug Metabolism and Disposition 2011, 39(9):1503-1510.
42. Kusuhara H., Sugiyama Y. In vitro-in vivo extrapolation of transporter-mediated clearance in the liver and kidney. Drug Metabolism and Pharmacokinetics 2009, 24(1):37-52.
43. Lankas G.R., Cartwright M.E., Umbenhauer D. P-glycoprotein deficiency in a subpopulation of CF-1 mice enhances avermectin-induced neurotoxicity. Toxicology and Applied Pharmacology 1997, 143(2):357-365.
44. Lee C.A. S8-Application of P-gp decision tree: what have we learned?. Drug Metabolism Reviews 2011, 43(S2):8.
45. Lee E.W., Lai Y., Zhang H., Unadkat J.D. Identification of the mitochondrial targeting signal of the human equilibrative nucleoside transporter 1 (hENT1): implications for interspecies differences in mitochondrial toxicity of fialuridine. Journal of Biological Chemistry 2006, 281(24):16700-16706.
46. Lee W.K., Reichold M., Edemir B., Ciarimboli G., Warth R., Koepsell H., et al. Organic cation transporters OCT1, 2, and 3 mediate high-affinity transport of the mutagenic vital dye ethidium in the kidney proximal tubule. Am. J. Physiol Renal Physiol 2009, 296,(6):F1504-F1513.
47. Link E., Parish S., Armitage J., Bowman L., Heath S., Matsuda F., et al. SLCO1B1 variants and statin-induced myopathy-a genomewide study. New England Journal of Medicine 2008, 359(8):789-799.
48. Lippmann E., Weidenfeller C., Svendsen C., Shusta E. Blood-brain barrier modeling with co-cultured neural progenitor cell-derived astrocytes and neurons. Journal of Neurochemistry 2011, 119(3):507-520.
49. Maeda K., Sugiyama Y. The use of hepatocytes to investigate drug uptake transporters. Methods in Molecular Biology 2010, 640:327-353.
50. Marion T.L., Perry C.H., St Claire R.L., Yue W., Brouwer K.L. Differential disposition of chenodeoxycholic acid versus taurocholic acid in response to acute troglitazone exposure in rat hepatocytes. Toxicological Sciences 2011, 120(2):371-380.
51. Menger R.F., Stutts W.L., Anbukumar D.S., Bowden J.A., Ford D.A., Yost R.A. MALDI mass spectrometric imaging of cardiac tissue following myocardial infarction in a rat coronary artery ligation model. Analytical Chemistry 2012, 84(2):1117-1125.
52. Morjani H., Madoulet C. Immunosuppressors as multidrug resistance reversal agents. Methods in Molecular Biology 2010, 596:433-446.
53. Motta P., Pons N., Pagliarusco S., Pellegatti M., Bonomo F. Casopitant: in vitro data and SimCyp simulation to predict in vivo metabolic interactions involving cytochrome P450 3A4. Drug Metabolism and Disposition 2011, 39(3):363-372.
54. Muller, M. (2006). Human ABC-Transporters. Available from: (February 20, 2012). http://nutrigene.4t.com/humanabc.htm.
55. Nakanishi T., Shibue Y., Fukuyama Y., Yoshida K., Fukuda H., Shirasaka Y., et al. Quantitative time-lapse imaging-based analysis of drug-drug interaction mediated by hepatobiliary transporter, multidrug resistance-associated protein 2, in sandwich-cultured rat hepatocytes. Drug Metabolism and Disposition 2011, 39(6):984-991.
56. Niemi M., Pasanen M.K., Neuvonen P.J. Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacological Reviews 2011, 63(1):157-181.
57. Nies A.T., Koepsell H., Damme K., Schwab M. Organic cation transporters (OCTs, MATEs), in vitro and in vivo evidence for the importance in drug therapy. Handbook of Experimental Pharmacology 2011, 201:105-167.
58. Ohtsuki S., Schaefer O., Kawakami H., Inoue T., Liehner S., Saito A., et al. Simultaneous absolute protein quantification of transporters, cytochromes P450, and UDP-glucuronosyltransferases as a novel approach for the characterization of individual human liver: comparison with mRNA levels and activities. Drug Metabolism and Disposition 2012, 40(1):83-92.
59. Okumu A., DiMaso M., Lobenberg R. Computer simulations using GastroPlus to justify a biowaiver for etoricoxib solid oral drug products. European Journal of Pharmaceutics and Biopharmaceutics 2009, 72(1):91-98.
60. Paine S.W., Menochet K., Denton R., McGinnity D.F., Riley R.J. Prediction of human renal clearance from preclinical species for a diverse set of drugs that exhibit both active secretion and net reabsorption. Drug Metabolism and Disposition 2011, 39(6):1008-1013.
61. Paine S.W., Parker A.J., Gardiner P., Webborn P.J., Riley R.J. Prediction of the pharmacokinetics of atorvastatin, cerivastatin, and indomethacin using kinetic models applied to isolated rat hepatocytes. Drug Metabolism and Disposition 2008, 36(7):1365-1374.
62. Peukert M., Matros A., Lattanzio G., Kaspar S., Abadia J., Mock H.P. Spatially resolved analysis of small molecules by matrix-assisted laser desorption/ionization mass spectrometric imaging (MALDI-MSI). New Phytology 2012, 193(3):806-815.
63. Poirier A., Cascais A.C., Funk C., Lave T. Prediction of pharmacokinetic profile of valsartan in humans based on in vitro uptake-transport data. Chemistry & Biodiversity 2009, 6(11):1975-1987.
64. Poirier A., Funk C., Scherrmann J.M., Lave T. Mechanistic modeling of hepatic transport from cells to whole body: application to napsagatran and fexofenadine. Molecular Pharmacology 2009, 6(6):1716-1733.
65. Poirier A., Lave T., Portmann R., Brun M.E., Senner F., Kansy M., et al. Design, data analysis, and simulation of in vitro drug transport kinetic experiments using a mechanistic in vitro model. Drug Metabolism and Disposition 2008, 36(12):2434-2444.
66. Polli J.W., Olson K.L., Chism J.P., John-Williams L.S., Yeager R.L., Woodard S.M., et al. An unexpected synergist role of P-glycoprotein and breast cancer resistance protein on the central nervous system penetration of the tyrosine kinase inhibitor lapatinib (N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine; GW572016). Drug Metabolism and Disposition 2009, 37(2):439-442.
67. Potschka, H. (2011). Role of CNS efflux drug transporters in antiepileptic drug delivery: overcoming CNS efflux drug transport, PM:22210135 (February 23, 2012).
68. Rakhit A., Pantze M.P., Fettner S., Jones H.M., Charoin J.E., Riek M., et al. The effects of CYP3A4 inhibition on erlotinib pharmacokinetics: computer-based simulation (SimCYP) predicts in vivo metabolic inhibition. European Journal of Clinical Pharmacology 2008, 64(1):31-41.
69. Reis J.M., Sinko B., Serra C.H. Parallel artificial membrane permeability assay (PAMPA) - Is it better than Caco-2 for human passive permeability prediction?. Mini-Reviews in Medicinal Chemistry 2010, 10(11):1071-1076.
70. Schaefer O., Ohtsuki S., Kawakami H., Inoue T., Liehner S., Saito A., et al. Absolute quantification and differential expression of drug transporters, cytochrome P450 enzymes, and UDP-glucuronosyltransferases in cultured primary human hepatocytes. Drug Metabolism and Disposition 2012, 40(1):93-103.
71. Shawahna R., Uchida Y., Decleves X., Ohtsuki S., Yousif S., Dauchy S., et al. Transcriptomic and quantitative proteomic analysis of transporters and drug metabolizing enzymes in freshly isolated human brain microvessels. Molecular Pharmacology 2011, 8(4):1332-1341.
72. Shirasaka Y., Suzuki K., Nakanishi T., Tamai I. Differential effect of grapefruit juice on intestinal absorption of statins due to inhibition of organic anion transporting polypeptide and/or P-glycoprotein. Journal of Pharmaceutical Sciences 2011, 100(9):3843-3853.
73. Shitara Y., Sugiyama Y. Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions. Pharmacology & Therapeutics 2006, 112(1):71-105.
74. Sugano K., Kansy M., Artursson P., Avdeef A., Bendels S., Di L., et al. Coexistence of passive and carrier-mediated processes in drug transport. Nature Reviews Drug Discovery 2010, 9(8):597-614.
75. Summerfield S., Lucas A., Porter R., Jeffrey P., Gunn R., Read K., et al. Toward an improved prediction of human in vivo brain penetration. Xenobiotica 2008, 38(12):1518-1535.
76. Svoboda M. Organic anion transporting polypeptides (OATPs): regulation of expression and function. Current Drug Metabolism 2011, 12(2):139-153.
77. Syvanen S., Luurtsema G., Molthoff C.F., Windhorst A.D., Huisman M.C., Lammertsma A.A., et al. (R)-[11C]verapamil PET studies to assess changes in P-glycoprotein expression and functionality in rat blood-brain barrier after exposure to kainate-induced status epilepticus. BMC Medical Imaging 2011, 11:1.
78. Takane H. [Genetic polymorphisms of SLCO1B1 for drug pharmacokinetics and its clinical implications]. Yakugaku Zasshi 2011, 131(11):1589-1594.
79. Tamaki A., Ierano C., Szakacs G., Robey R.W., Bates S.E. The controversial role of ABC transporters in clinical oncology. Essays in Biochemistry 2011, 50(1):209-232.
80. Tamhane M., Chakilam A., Jayaraj A., Thakkar V., Taft D. Comparative renal excretion of VX-702, a novel p38 MAPK inhibitor, and methotrexate in the perfused rat kidney model. Drug Development and Industrial Pharmacy 2010, 36(3):315-322.
81. Taub M.E., Mease K., Sane R.S., Watson C.A., Chen L., Ellens H., et al. Digoxin is not a substrate for organic anion-transporting polypeptide transporters OATP1A2, OATP1B1, OATP1B3, and OATP2B1 but is a substrate for a sodium-dependent transporter expressed in HEK293 cells. Drug Metabolism and Disposition 2011, 39(11):2093-2102.
82. Tirona R. Molecular mechanisms of drug transporter regulation. Handbook of Experimental Pharmacology 2011, 201:372-402.
83. Tucker T.G., Milne A.M., Fournel-Gigleux S., Fenner K.S., Coughtrie M.W. Absolute immunoquantification of the expression of ABC transporters P-glycoprotein, breast cancer resistance protein and multidrug resistance-associated protein 2 in human liver and duodenum. Biochemical Pharmacology 2012, 83(2):729-785.
84. Tzvetkov M.V., Saadatmand A.R., Bokelmann K., Meineke I., Kaiser R., Brockmoller J. Effects of OCT1 polymorphisms on the cellular uptake, plasma concentrations and efficacy of the 5-HT(3) antagonists tropisetron and ondansetron. Pharmacogenomics Journal 2012, 12(1):22-29.
85. Tzvetkov M.V., Saadatmand A.R., Lotsch J., Tegeder I., Stingl J.C., Brockmoller J. Genetically polymorphic OCT1: another piece in the puzzle of the variable pharmacokinetics and pharmacodynamics of the opioidergic drug tramadol. Clinical Pharmacology & Therapeutics 2011, 90(1):143-150.
86. Tzvetkov M.V., Vormfelde S.V., Balen D., Meineke I., Schmidt T., Sehrt D., et al. The effects of genetic polymorphisms in the organic cation transporters OCT1, OCT2, and OCT3 on the renal clearance of metformin. Clinical Pharmacology & Therapeutics 2009, 86(3):299-306.
87. Umehara K.I., Iwatsubo T., Noguchi K., Kamimura H. Comparison of the kinetic characteristics of inhibitory effects exerted by biguanides and H2-blockers on human and rat organic cation transporter-mediated transport: Insight into the development of drug candidates. Xenobiotica 2007, 37,(6):618-634.
88. Urakami Y., Kimura N., Okuda M., Inui K. Creatinine transport by basolateral organic cation transporter hOCT2 in the human kidney. Pharm. Res. 2004, 21,(6):976-981.
89. van de Steeg E., Wagenaar E., van der Kruijssen C.M., Burggraaff J.E., de Waart D.R., et al. Organic anion transporting polypeptide 1a/1b-knockout mice provide insights into hepatic handling of bilirubin, bile acids, and drugs. The Journal of Clinical Investigation 2010, 120(8):2942-2952.
90. Van Waterschoot R.A., Lagas J.S., Wagenaar E., Rosing H., Beijnen J.H., Schinkel A.H. Individual and combined roles of CYP3A, P-glycoprotein (MDR1/ABCB1) and MRP2 (ABCC2) in the pharmacokinetics of docetaxel. International Journal of Cancer 2010, 127(12):2959-2964.
91. Vladutiu G., Isackson P. SLCO1B1 variants and statin-induced myopathy. New England Journal of Medicine 2008, 359(8):789-799.
92. Vlaming M.L., van E.A., Pala Z., Wagenaar E., van de Wetering K., van T.O., et al. Abcc2 (Mrp2), Abcc3 (Mrp3), and Abcg2 (Bcrp1) are the main determinants for rapid elimination of methotrexate and its toxic metabolite 7-hydroxymethotrexate in vivo. Molecular Cancer Therapeutics 2009, 8(12):3350-3359.
93. Vlaming M.L., van E.A., van de Steeg E., Pala Z., Wagenaar E., van T.O., et al. Impact of abcc2 [multidrug resistance-associated protein (MRP) 2], abcc3 (MRP3), and abcg2 (breast cancer resistance protein) on the oral pharmacokinetics of methotrexate and its main metabolite 7-hydroxymethotrexate. Drug Metabolism and Disposition 2011, 39(8):1338-1344.
94. Wang Z., Zhou Q., Kruh G.D., Gallo J.M. Dose-dependent disposition of methotrexate in abcc2 and abcc3 gene knockout murine models. Drug Metabolism and Disposition 2011, 39(11):2155-2161.
95. Wang Z.J., Yin O.Q., Tomlinson B., Chow M.S. OCT2 polymorphisms and in-vivo renal functional consequence: studies with metformin and cimetidine. Pharmacogenetics and Genomics 2008, 18(7):637-645.
96. Watanabe T., Kusuhara H., Sugiyama Y. Application of physiologically based pharmacokinetic modeling and clearance concept to drugs showing transporter-mediated distribution and clearance in humans. J.Pharmacokinet.Pharmacodyn. 2010, 37(6):575-590.
97. Watanabe T., Kusuhara H., Watanabe T., Debori Y., Maeda K., Kondo T., et al. Prediction of the overall renal tubular secretion and hepatic clearance of anionic drugs and a renal drug-drug interaction involving organic anion transporter 3 in humans by in vitro uptake experiments. Drug Metabolism and Disposition 2011, 39(6):1031-1038.
98. Webborn P.J., Parker A.J., Denton R.L., Riley R.J. In vitro-in vivo extrapolation of hepatic clearance involving active uptake: theoretical and experimental aspects. Xenobiotica 2007, 37(10-11):1090-1109.
99. Wen J., Xiong Y. OATP1B1 388A>G polymorphism and pharmacokinetics of pitavastatin in Chinese healthy volunteers. Journal of Clinical Pharmacy and Therapeutics 2010, 35(1):99-104.
100. Wilby A.J., Maeda K., Courtney P.F., Debori Y., Webborn P.J., Kitamura Y., et al. Hepatic uptake in the dog: comparison of uptake in hepatocytes and human embryonic kidney cells expressing dog organic anion-transporting polypeptide 1B4. Drug Metabolism and Disposition 2011, 39(12):2361-2369.
101. Wolf K.K., Vora S., Webster L.O., Generaux G.T., Polli J.W., Brouwer K.L. Use of cassette dosing in sandwich-cultured rat and human hepatocytes to identify drugs that inhibit bile acid transport. Toxicology In Vitro 2010, 24(1):297-309.
102. Yamada A., Maeda K., Ishiguro N., Tsuda Y., Igarashi T., Ebner T., et al. The impact of pharmacogenetics of metabolic enzymes and transporters on the pharmacokinetics of telmisartan in healthy volunteers. Pharmacogenetics and Genomics 2011, 21(9):523-530.
103. Yang J., Milton M., Yu S., Liao M., Liu N., Wu J., et al. P-glycoprotein and breast cancer resistance protein affect disposition of tandutinib, a tyrosine kinase inhibitor. Drug Metabolism Letters 2010, 4(4):201-212.
104. Yonezawa A., Inui K. Importance of the multidrug and toxin extrusion MATE/SLC47A family to pharmacokinetics, pharmacodynamics/toxicodynamics and pharmacogenomics. British Journal of Pharmacology 2011, 164(7):1817-1825.
105. Zhang L., Zhang Y., Strong J., Reynolds K., Huang S. A regulatory viewpoint on transporter-based drug interactions. Xenobiotica 2008, 37(7, 8):709-724.
106. Zolk O., Solbach T.F., Konig J., Fromm M.F. Functional characterization of the human organic cation transporter 2 variant p.270Ala>Ser. Drug Metabolism and Disposition 2009, 37(6):1312-1318.
107. Zolk O., Solbach T.F., Konig J., Fromm M.F. Structural determinants of inhibitor interaction with the human organic cation transporter OCT2 (SLC22A2). Naunyn Schmiedebergs Arch. Pharmacol 2009, 379,(4):337-348.